Frontiers in Immunology (May 2022)

Distinct Immunological Profiles Help in the Maintenance of Salivary Secretory IgA Production in Mild Symptoms COVID-19 Patients

  • Juliana de Melo Batista dos Santos,
  • Jonatas Bussador do Amaral,
  • Carolina Nunes França,
  • Fernanda Rodrigues Monteiro,
  • Anuska Marcelino Alvares-Saraiva,
  • Sandra Kalil,
  • Edison Luiz Durigon,
  • Edison Luiz Durigon,
  • Danielle Bruna Leal Oliveira,
  • Danielle Bruna Leal Oliveira,
  • Silvia Sanches Rodrigues,
  • Debora Heller,
  • Debora Heller,
  • Debora Heller,
  • Eliane Aparecida Rosseto Welter,
  • João Renato Rebello Pinho,
  • João Renato Rebello Pinho,
  • João Renato Rebello Pinho,
  • Rodolfo P. Vieira,
  • Rodolfo P. Vieira,
  • Rodolfo P. Vieira,
  • André Luis Lacerda Bachi,
  • André Luis Lacerda Bachi

DOI
https://doi.org/10.3389/fimmu.2022.890887
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundRelevant aspects regarding the SARS-CoV-2 pathogenesis and the systemic immune response to this infection have been reported. However, the mucosal immune response of the upper airways two months after SARS-CoV-2 infection in patients with mild/moderate symptoms is still not completely described. Therefore, we investigated the immune/inflammatory responses of the mucosa of the upper airways of mild/moderate symptom COVID-19 patients two months after the SARS-CoV-2 infection in comparison to a control group composed of non-COVID-19 healthy individuals.MethodsA cohort of 80 volunteers (age 37.2 ± 8.2), including non-COVID-19 healthy individuals (n=24) and COVID-19 patients (n=56) who presented mild/moderate symptoms during a COVID-19 outbreak in Brazil in November and December of 2020. Saliva samples were obtained two months after the COVID-19 diagnosis to assess the levels of SIgA by ELISA and the cytokines by multiplex analysis.ResultsSalivary levels of SIgA were detected in 39 volunteers into the COVID-19 group and, unexpectedly, in 14 volunteers in the control group. Based on this observation, we distributed the volunteers of the control group into without SIgA or with SIgA sub-groups, and COVID-19 group into without SIgA or with SIgA sub-groups. Individuals with SIgA showed higher levels of IL-10, IL-17A, IFN-γ, IL-12p70, IL-13, and IFN-α than those without SIgA. In intergroup analysis, the COVID-19 groups showed higher salivary levels of IL-10, IL-13, IL-17A, and IFN-α than the control group. No statistical differences were verified in the salivary levels of IL-6 and IFN-β. Lower IL-12p70/IL-10 and IFN-γ/IL-10 ratios were found in the control group without SIgA than the control group with SIgA and the COVID-19 group with SIgA.ConclusionWe were able to present, for the first time, that associations between distinct immunological profiles can help the mucosal immunity to maintain the salivary levels of SIgA in COVID-19 patients two months after the SARS-CoV-2 infection.

Keywords